Member Info for davidpqz

Has anyone tried to estimate this company's true value?

Truth? Lucidity? WTF RU talking about?

The charts predict the moves years before they happen? So what's the Lancaster oil/water level going to be in a year's time. ROFL

"The Company is releasing a series of historic shareholding announcements which have just been notified to it but which represent dealings that took place in 2019."
And for which presumably, they failed to issue an RNS?

Abbott Labs less than 95, 98

Apologies for banging on about this but GDR's 'accuracy' is the best as far as I can see. These figures can be hard to root out so if anyone has more recent figures then let's have them here. GDR's sensitivity is 100% - if someone who is tested is infected it will without fail, identify them. Specificity is 98.2% which means a small proportion who are disease free will be identified as having it.
Here are the figures for other companies:
Senitivity, Specificity: SONA 96, 96 QUIDEL 80, 100 NOVACYTE 88,90
ABBOTT LABS 98 GENEDRIVE 100, 98.2

When it has a medical application?

Some posters on here seem to think that the disease has gone away. You can fact check here:
https://www.worldometers.info/coronavirus/

It says it on the tin "Applied Graphene" :-)

What was the "interference" and what was its cause? At the risk of inviting loads of nasty abuse, is it possible that both wells were close to the water level? To be honest, I've almost given up on BB's but one or two of you seem to understand the business and I suspect HUR might be currently greatly undervalued.

OlderandWiser(?). Mr Market is a crazy fellow – who said that?

PL75. Suggest you study geometrical progression. It is your kind of uninformed aggressive comment which make these BB's so entertaining – a bit like listening to Trump (by the way have you tried bleach yet?).

Genedrive has a test which which is 100% sensitive and 98.2% specific and they are marketing it now.

I always run these figures through a little spreadsheet which I have set up with a population of 10,000 and an incidence of the disease of 1% i.e. 100 people truly have the disease. In this case where both sens and spec are 96% the result is 96 true positives and 396 false positives with 4 false negatives free to carry on infecting. This test on its own without further retesting isn't going to be adequate.

Thanks Grizzly. That's a very valuable contribution . As I read it, JCyte may be a bit further ahead on clinical trials but RENE is getting much better results.

All the while you are focussed on the share price you are not looking at the fundamentals. You are like someone driving with their eyes in the rear view mirror. Who has a better proposition than GDR and how do you evaluate that? How great is the demand for their product. You are (or should be) in the business of answering those questions snd predicting the future and the sp is of limited use because as one of the great prophets of investing said "Mr Market is a crazy guy".
Apologies for the rant I,ve just enjoyed a virtual drink with an old buddy and I just wanted yo get it off my chest. Good luck one and all.

Read the last sentence. It's on the BBC somewhere (this is from Wiki) but I can't find it again. Basically, US has bought up nearly the total supply of remdesivir for the next three months and bugger the rest of the world.

On 29 June 2020, Gilead announced that it had set the price of remdesivir at US$390 per vial for the governments of developed countries, including the United States, and US$520 for U.S. private health insurance companies.[79] The expected course of treatment is six vials over five days for a total cost of US$2,340.[79] Being a repurposed drug, the minimum production cost for remdesivir is estimated at US$0.93 per day of treatment.[80] On that same day, HHS announced an unusual agreement with Gilead in which HHS agreed to Gilead's wholesale acquisition price, HHS would continue to work together with state governments and drug wholesaler AmerisourceBergen to allocate shipments of remdesivir vials to American hospitals through the end of September 2020, and in exchange, during that three-month timeframe (July, August, and September), American patients would be allocated over 90% of Gilead's projected remdesivir output of more than 500,000 treatment courses

S&P is down on resurgence of Covid in US. Also, it is said that the smart money is out of the market - that the recent rally was driven by PI's who as you know, can be very excitable but this is a share that should thrive on bad news. I've seen this sort of lag with gold co.s at the beginning of the pandemic, initially they went down with the rest of the market before reversing when people realised that bad news is good for gold.

https://www.bbc.co.uk/news/health-52906909

Prospero. I made a purchase this morning which shows as a sell. The 'sell'or 'buy' label is a guess based on proximity to the bid or offer.

Safy. I am not aware of better sensitivity or specificity results than GDR's so I am quite encouraged by this (idiotic comments to the contrary).
The main antigen tests in use appear to be Abbott and Novacyte. Novacyte has a sens and spec of 88% and 90% and there's a lot of controversy over Abbott but it would appear their sens is <95% and spec > 98%. The French HAS health authority interestingly is refusing to reimburse labs using the Novacyte tests.
The field is of course in constant flux so my info may be out of date
I think it is an area we should keep an eye on as it is crucial to the adoption of tests.